Macquarie Group LTD Allogene Therapeutics, Inc. Call Options Transaction History
Macquarie Group LTD
- $86.4 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALLO
# of Institutions
176Shares Held
139MCall Options Held
75.8KPut Options Held
52.8K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$48.7 Million1.1% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$42.8 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR10.9MShares$28.3 Million9.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8MShares$20.8 Million0.0% of portfolio
-
State Street Corp Boston, MA7.25MShares$18.8 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $374M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...